quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:31:23·56d
SECFiling
Aclaris Therapeutics Inc. logo

SEC Form 10-K filed by Aclaris Therapeutics Inc.

ACRS· Aclaris Therapeutics Inc.
Health Care
Full content unavailable. See the original source below.
Original source

Companies

  • ACRS
    Aclaris Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Apr 16UpdateOppenheimer$10.00
  • Jul 10UpdatePiper Sandler$6.00
  • May 28UpdateWedbush$8.00
  • Mar 18UpdateCantor Fitzgerald-
  • Dec 23UpdateH.C. Wainwright$20.00
  • Nov 20UpdateCantor Fitzgerald-

Related

  • SEC1d
    SEC Form DEFA14A filed by Aclaris Therapeutics Inc.
  • SEC1d
    SEC Form DEF 14A filed by Aclaris Therapeutics Inc.
  • ANALYST8d
    Oppenheimer initiated coverage on Aclaris Therapeutics with a new price target
  • PR16d
    Aclaris Therapeutics to Participate in the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference
  • SEC16d
    SEC Form SCHEDULE 13G filed by Aclaris Therapeutics Inc.
  • PR28d
    Results Presented at 2026 American Academy of Dermatology (AAD) Annual Meeting Provide Additional Support for the Therapeutic Potential of ATI-2138
  • SEC28d
    Amendment: SEC Form SCHEDULE 13G/A filed by Aclaris Therapeutics Inc.
  • PR35d
    Aclaris Therapeutics Announces Poster on Results from Phase 2a Trial of ATI-2138 at the 2026 American Academy of Dermatology (AAD) Annual Meeting
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022